Short Diagnosis-To-Treatment Interval Is Associated With High Risk and Poor Outcomes in Diffuse Large B-Cell Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.84_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

BCL-2 Protein Frequency in Patients With High-Risk Diffuse Large B-Cell Lymphoma

Sao Paulo Medical Journal
Medicine
2010English

Biomarkers of Diffuse Large B-Cell Lymphoma: Impact on Diagnosis, Treatment, and Prognosis

Current Biomarker Findings
BiochemistryClinical Biochemistry
2013English

Diffuse Large B-Cell Lymphoma With Primary Treatment Failure: Ultra-High Risk Features and Benchmarking for Experimental Therapies

American Journal of Hematology
Hematology
2017English

Diffuse Large B-Cell Lymphoma

2020English

Direct Costs Associated With Relapsed Diffuse Large B‐Cell Lymphoma Therapies

Oncologist
Cancer ResearchMedicineOncology
2019English

Plasma Immunoprofiling of Patients With High-Risk Diffuse Large B-Cell Lymphoma: A Nordic Lymphoma Group Study

Blood Cancer Journal
OncologyHematology
2016English

Oncologist Volume and Outcomes in Older Adults Diagnosed With Diffuse Large B Cell Lymphoma

Cancer
Cancer ResearchOncology
2018English

Hitting Back at Lymphoma: How Do Modern Diagnostics Identify High‐risk Diffuse Large B‐cell Lymphoma Subsets and Alter Treatment?

Cancer
Cancer ResearchOncology
2019English

High-Risk Patients With Diffuse Large B-Cell Lymphoma Are Not Enrolled on Clinical Trials

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy